NCT03601962View on ClinicalTrials.gov

Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

NATerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
XerostomiaAsialiaHyposalivationMouth Dryness
Interventions
DIETARY_SUPPLEMENT

Aqualief

400mg oral mucoadesive tablets

OTHER

Placebo

400mg Placebo oral mucoadesive tablets

Trial Locations (1)

20100

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Sponsors
All Listed Sponsors
collaborator

Latis S.r.l.

INDUSTRY

lead

Helsinn Healthcare SA

INDUSTRY